Aripiprazole (English Wikipedia)

"Otsuka's Abilify Maintena: dual drug expiry signals sales decline - P…". archive.li. 23 February 2025. Archived from the original on 23 February 2025. Retrieved 23 February 2025.{{cite web}}: CS1 maint: bot: original URL status unknown (link)

bloomberg.com

Decker S, Randall T (15 November 2010). "Bristol-Myers Partner Otsuka Wins Abilify Ruling – Bloomberg Business". Bloomberg L.P. Archived from the original on 22 July 2016. Retrieved 13 May 2015.

books.google.com

Haddad P, Haddad PM, Dursun S, Deakin B (2004). Adverse Syndromes and Psychiatric Drugs: A Clinical Guide. OUP Oxford. pp. 207–216. ISBN 978-0-19-852748-0. Archived from the original on 10 January 2023. Retrieved 19 September 2020.
Sacchetti E, Vita A, Siracusano A, Fleischhacker W (2013). Adherence to Antipsychotics in Schizophrenia. Springer Science & Business Media. p. 85. ISBN 9788847026797. Archived from the original on 10 January 2023. Retrieved 19 September 2020.
Behere PB, Das A, Behere AP (2018). Clinical Psychopharmacology: An Update. Springer. p. 66. ISBN 9789811320927. Archived from the original on 4 July 2024. Retrieved 19 September 2020.

canada.ca

health-products.canada.ca

"Abilify Product information". Health Canada. 19 March 2018. Retrieved 16 February 2025.
"Abilify Asimtufii Product information". Health Canada. 17 January 2025. Retrieved 16 February 2025.
"Abilify Maintena Product information". Health Canada. 27 March 2014. Retrieved 16 February 2025.

clincalc.com

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Aripiprazole Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

corporate-ir.net

phx.corporate-ir.net

"Barr Confirms Filing an Application with a Paragraph IV Certification for Abilify Tablets" (Press release). Barr Pharmaceuticals, Inc. 20 March 2007. Archived from the original on 16 September 2018. Retrieved 23 December 2008.

doi.org

Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, et al. (January 2014). "Aripiprazole versus other atypical antipsychotics for schizophrenia". The Cochrane Database of Systematic Reviews. 2014 (1): CD006569. doi:10.1002/14651858.CD006569.pub5. PMC 4164478. PMID 24385408.
Belgamwar RB, El-Sayeh HG (August 2011). "Aripiprazole versus placebo for schizophrenia". The Cochrane Database of Systematic Reviews (8): CD006622. doi:10.1002/14651858.CD006622.pub2. PMID 21833956.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N (11 July 2019). "Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis". The Lancet. 394 (10202): 939–951. doi:10.1016/S0140-6736(19)31135-3. PMC 6891890. PMID 31303314.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". The Lancet. 382 (9896): 951–962. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019. S2CID 32085212.
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. (February 2013). "World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects". The World Journal of Biological Psychiatry. 14 (1): 2–44. doi:10.3109/15622975.2012.739708. PMID 23216388. S2CID 28750563.
Barnes TR (May 2011). "Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology". Journal of Psychopharmacology. 25 (5): 567–620. doi:10.1177/0269881110391123. PMID 21292923. S2CID 40089561.
Brown R, Taylor MJ, Geddes J (December 2013). "Aripiprazole alone or in combination for acute mania". The Cochrane Database of Systematic Reviews. 2013 (12): CD005000. doi:10.1002/14651858.CD005000.pub2. PMC 11330668. PMID 24346956.
De Fruyt J, Deschepper E, Audenaert K, Constant E, Floris M, Pitchot W, et al. (May 2012). "Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis". Journal of Psychopharmacology. 26 (5): 603–617. doi:10.1177/0269881111408461. hdl:2268/196468. PMID 21940761. S2CID 57249815.
Gitlin M, Frye MA (May 2012). "Maintenance therapies in bipolar disorders". Bipolar Disorders. 14 (Suppl 2): 51–65. doi:10.1111/j.1399-5618.2012.00992.x. PMID 22510036. S2CID 21101054.
de Bartolomeis A, Perugi G (October 2012). "Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: from acute mania to long-term maintenance". Expert Opinion on Pharmacotherapy. 13 (14): 2027–2036. doi:10.1517/14656566.2012.719876. PMID 22946707. S2CID 39065786.
Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (March 2013). "Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes". PLOS Medicine. 10 (3): e1001403. doi:10.1371/journal.pmed.1001403. PMC 3595214. PMID 23554581.
Nelson JC, Papakostas GI (September 2009). "Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials". The American Journal of Psychiatry. 166 (9): 980–991. doi:10.1176/appi.ajp.2009.09030312. PMID 19687129.
Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S (December 2010). "Second-generation antipsychotics for major depressive disorder and dysthymia". The Cochrane Database of Systematic Reviews (12): CD008121. doi:10.1002/14651858.CD008121.pub2. PMC 11994262. PMID 21154393.
Azuma J, Hasunuma T, Kubo M, Miyatake M, Koue T, Higashi K, et al. (January 2012). "The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine". European Journal of Clinical Pharmacology. 68 (1): 29–37. doi:10.1007/s00228-011-1094-4. PMC 3249179. PMID 21739267.
Hahn M, Roll SC (December 2016). "Dosing Recommendations of Aripiprazole Depot with Strong Cytochrome P450 3A4 Inhibitors: A Relapse Risk". Drug Safety: Case Reports. 3 (1): 5. doi:10.1007/s40800-016-0027-7. PMC 5005780. PMID 27747685.
Jallaq SA, Verba M, Strawn JR, Martin LJ, DelBello MP, Ramsey LB (February 2021). "CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders". Journal of Child and Adolescent Psychopharmacology. 31 (1): 56–62. doi:10.1089/cap.2020.0058. PMC 8255312. PMID 32845723.
Hoffelt C, Gross T (January 2016). "A review of significant pharmacokinetic drug interactions with antidepressants and their management". The Mental Health Clinician. 6 (1): 35–41. doi:10.9740/mhc.2016.01.035. PMC 6009245. PMID 29955445.
Hirsch LE, Pringsheim T (June 2016). "Aripiprazole for autism spectrum disorders (ASD)". The Cochrane Database of Systematic Reviews. 2016 (6): CD009043. doi:10.1002/14651858.CD009043.pub3. PMC 7120220. PMID 27344135.
Janik P, Szejko N (2018). "Aripiprazole in treatment of Gilles de la Tourette syndrome – New therapeutic option". Neurologia I Neurochirurgia Polska. 52 (1): 84–87. doi:10.1016/j.pjnns.2017.10.015. PMID 29154107. Archived from the original on 24 December 2022. Retrieved 20 November 2021.
Müller-Vahl KR, Szejko N, Verdellen C, Roessner V, Hoekstra PJ, Hartmann A, et al. (March 2022). "European clinical guidelines for Tourette syndrome and other tic disorders: summary statement". European Child & Adolescent Psychiatry. 31 (3): 377–382. doi:10.1007/s00787-021-01832-4. PMC 8940881. PMID 34244849.
Wang S, Wei YZ, Yang JH, Zhou YM, Cheng YH, Yang C, et al. (August 2017). "The efficacy and safety of aripiprazole for tic disorders in children and adolescents: A systematic review and meta-analysis". Psychiatry Research. 254: 24–32. doi:10.1016/j.psychres.2017.04.013. PMID 28441584. S2CID 13792422.
Cox JH, Seri S, Cavanna AE (2016). "Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders". Pediatric Health, Medicine and Therapeutics. 7: 57–64. doi:10.2147/PHMT.S87121. PMC 5683285. PMID 29388585.
Zheng W, Li XB, Xiang YQ, Zhong BL, Chiu HF, Ungvari GS, et al. (January 2016). "Aripiprazole for Tourette's syndrome: a systematic review and meta-analysis". Human Psychopharmacology. 31 (1): 11–18. doi:10.1002/hup.2498. PMID 26310194. S2CID 5353158.
Yang CS, Huang H, Zhang LL, Zhu CR, Guo Q (July 2015). "Aripiprazole for the treatment of tic disorders in children: a systematic review and meta-analysis". BMC Psychiatry. 15: 179. doi:10.1186/s12888-015-0504-z. PMC 4518630. PMID 26220447.
Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J (November 2014). "Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis". BMC Psychiatry. 14 (1): 317. doi:10.1186/s12888-014-0317-5. PMC 4262998. PMID 25432131.
Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J (November 2014). "Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis". BMC Psychiatry. 14: 317. doi:10.1186/s12888-014-0317-5. PMC 4262998. PMID 25432131.
Fornaro M, Gabrielli F, Mattei C, Vinciguerra V, Fornaro P (December 2008). "Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report". Annals of General Psychiatry. 7 (1): 26. doi:10.1186/1744-859X-7-26. PMC 2621216. PMID 19105842.
Pignon B, Tezenas du Montcel C, Carton L, Pelissolo A (November 2017). "The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders". Current Psychiatry Reports. 19 (12): 103. doi:10.1007/s11920-017-0847-x. PMID 29110139. S2CID 41312623.
Grall-Bronnec M, Sauvaget A, Perrouin F, Leboucher J, Etcheverrigaray F, Challet-Bouju G, et al. (February 2016). "Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review". Journal of Clinical Psychopharmacology. 36 (1): 63–70. doi:10.1097/JCP.0000000000000444. PMC 4700874. PMID 26658263.
Moncrieff J (July 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655. S2CID 6267180.
Skov L, Johansen SS, Linnet K (January 2015). "Postmortem femoral blood reference concentrations of aripiprazole, chlorprothixene, and quetiapine". Journal of Analytical Toxicology. 39 (1): 41–44. doi:10.1093/jat/bku121. PMID 25342720.
Westerink BH, Kawahara Y, De Boer P, Geels C, De Vries JB, Wikström HV, et al. (January 2001). "Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum". European Journal of Pharmacology. 412 (2): 127–138. doi:10.1016/S0014-2999(00)00935-3. PMID 11165224.
Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. (August 2003). "Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology". Neuropsychopharmacology. 28 (8): 1400–1411. doi:10.1038/sj.npp.1300203. PMID 12784105.
Mohr P, Masopust J, Kopeček M (25 January 2022). "Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?". Frontiers in Psychiatry. 12: 781946. doi:10.3389/fpsyt.2021.781946. PMC 8821167. PMID 35145438.
Keck PE, McElroy SL (April 2003). "Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic". Expert Opinion on Investigational Drugs. 12 (4): 655–662. doi:10.1517/13543784.12.4.655. PMID 12665420. S2CID 8654102.
Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. (March 2003). "H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs". Neuropsychopharmacology. 28 (3): 519–526. doi:10.1038/sj.npp.1300027. PMID 12629531.
Gaitonde SA, Avet C, de la Fuente Revenga M, Blondel-Tepaz E, Shahraki A, Pastor AM, et al. (September 2024). "Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor". Mol Psychiatry. 29 (9): 2753–2764. doi:10.1038/s41380-024-02531-7. PMC 11420065. PMID 38561467.
Starrenburg FC, Bogers JP (April 2009). "How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins". European Psychiatry. 24 (3): 164–170. doi:10.1016/j.eurpsy.2009.01.001. PMID 19285836. S2CID 42636469.
Davies MA, Sheffler DJ, Roth BL (2004). "Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology". CNS Drug Reviews. 10 (4): 317–336. doi:10.1111/j.1527-3458.2004.tb00030.x. PMC 6741761. PMID 15592581.
Pae CU, Serretti A, Patkar AA, Masand PS (2008). "Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence". CNS Drugs. 22 (5): 367–388. doi:10.2165/00023210-200822050-00002. PMID 18399707. S2CID 19757151.
Tuplin EW, Holahan MR (November 2017). "Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity". Current Neuropharmacology. 15 (8): 1192–1207. doi:10.2174/1570159X15666170413115754. PMC 5725548. PMID 28412910.
Wood M, Reavill C (June 2007). "Aripiprazole acts as a selective dopamine D2 receptor partial agonist". Expert Opinion on Investigational Drugs. 16 (6): 771–775. doi:10.1517/13543784.16.6.771. PMID 17501690. S2CID 42171115.
Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, et al. (December 2008). "Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride". Neuropsychopharmacology. 33 (13): 3111–3125. doi:10.1038/npp.2008.33. PMID 18418366.
Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, et al. (August 2002). "Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride". Neuropsychopharmacology. 27 (2): 248–259. doi:10.1016/S0893-133X(02)00304-4. PMID 12093598.
Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (April 2002). "The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor". European Journal of Pharmacology. 441 (3): 137–140. doi:10.1016/S0014-2999(02)01532-7. PMID 12063084.
Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S (September 2007). "Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study". The American Journal of Psychiatry. 164 (9): 1411–1417. doi:10.1176/appi.ajp.2007.06091479. PMID 17728427.
Mailman RB, Murthy V (May 2010). "Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?". Current Pharmaceutical Design. 16 (5): 488–501. doi:10.2174/138161210790361461. PMC 2958217. PMID 19909227.
Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. (July 2002). "Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors". The Journal of Pharmacology and Experimental Therapeutics. 302 (1): 381–389. doi:10.1124/jpet.102.033175. PMID 12065741. S2CID 12919430.
Urban JD, Vargas GA, von Zastrow M, Mailman RB (January 2007). "Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways". Neuropsychopharmacology. 32 (1): 67–77. doi:10.1038/sj.npp.1301071. PMID 16554739. S2CID 31846731.
Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, et al. (August 2002). "Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride". Neuropsychopharmacology. 27 (2): 248–259. doi:10.1016/S0893-133X(02)00304-4. PMID 12093598. S2CID 26101524.
Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, et al. (December 2008). "Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride". Neuropsychopharmacology. 33 (13): 3111–3125. doi:10.1038/npp.2008.33. PMID 18418366. S2CID 33993650.
Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. (August 2003). "Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology". Neuropsychopharmacology. 28 (8): 1400–1411. doi:10.1038/sj.npp.1300203. PMID 12784105. S2CID 22568982.
"In This Issue". Am J Psychiatry. 165 (8): A46. August 2008. doi:10.1176/appi.ajp.2008.165.8.A46.
Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J (February 2006). "Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms". Biochemical Pharmacology. 71 (4): 521–529. doi:10.1016/j.bcp.2005.11.007. PMID 16336943.
Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, et al. (June 1999). "Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes". Neuropsychopharmacology. 20 (6): 612–627. doi:10.1016/S0893-133X(98)00099-2. PMID 10327430.
Kessler RM (September 2007). "Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?". The American Journal of Psychiatry. 164 (9): 1310–1312. doi:10.1176/appi.ajp.2007.07071043. PMID 17728411. S2CID 1891586.
Jørgensen A, Overø KF (1980). "Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels". Acta Psychiatrica Scandinavica. Supplementum. 279: 41–54. doi:10.1111/j.1600-0447.1980.tb07082.x. PMID 6931472.
Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA (April 1979). "Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man". British Journal of Clinical Pharmacology. 7 (4): 325–31. doi:10.1111/j.1365-2125.1979.tb00941.x. PMC 1429660. PMID 444352.
Beresford R, Ward A (January 1987). "Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis". Drugs. 33 (1): 31–49. doi:10.2165/00003495-198733010-00002. PMID 3545764.
Reyntigens AJ, Heykants JJ, Woestenborghs RJ, Gelders YG, Aerts TJ (1982). "Pharmacokinetics of haloperidol decanoate. A 2-year follow-up". International Pharmacopsychiatry. 17 (4): 238–46. doi:10.1159/000468580. PMID 7185768.
Serezhkin VN, Savchenkov AV (2020). "Application of the Method of Molecular Voronoi–Dirichlet Polyhedra for Analysis of Noncovalent Interactions in Aripiprazole Polymorphs". Crystal Growth & Design. 20 (3): 1997–2003. Bibcode:2020CrGrD..20.1997S. doi:10.1021/acs.cgd.9b01645. S2CID 213824513.
Warren LR, McGowan E, Renton M, Morrison CA, Funnell NP (October 2021). "Direct evidence for distinct colour origins in ROY polymorphs". Chemical Science. 12 (38): 12711–12718. doi:10.1039/d1sc04051k. PMC 8494124. PMID 34703557.
Grady MA, Gasperoni TL, Kirkpatrick P (June 2003). "Aripiprazole". Nature Reviews. Drug Discovery. 2 (6): 427–428. doi:10.1038/nrd1114. PMID 12790153.
de Bartolomeis A, Tomasetti C, Iasevoli F (September 2015). "Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism". CNS Drugs. 29 (9): 773–799. doi:10.1007/s40263-015-0278-3. PMC 4602118. PMID 26346901.
Kikuchi T, Maeda K, Suzuki M, Hirose T, Futamura T, McQuade RD (June 2021). "Discovery research and development history of the dopamine D₂ receptor partial agonists, aripiprazole and brexpiprazole". Neuropsychopharmacology Reports. 41 (2): 134–143. doi:10.1002/npr2.12180. PMC 8340839. PMID 33960741.
Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, et al. (July 1995). "7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity". The Journal of Pharmacology and Experimental Therapeutics. 274 (1): 329–336. doi:10.1016/S0022-3565(25)10600-9. PMID 7616416.
Citrome L (2015). "Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil". Expert Review of Clinical Pharmacology. 9 (2): 169–186. doi:10.1586/17512433.2016.1121809. PMID 26573020. S2CID 207208248.
Casey AB, Canal CE (June 2017). "Classics in Chemical Neuroscience: Aripiprazole". ACS Chemical Neuroscience. 8 (6): 1135–1146. doi:10.1021/acschemneuro.7b00087. PMC 5495458. PMID 28368577.
De Crescenzo F, Cortese S, Adamo N, Janiri L (February 2017). "Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review". Evidence-Based Mental Health. 20 (1): 4–11. doi:10.1136/eb-2016-102415. PMC 10699262. PMID 27993933. S2CID 24904076.
Buoli M, Serati M, Cahn W (2016). "Alternative pharmacological strategies for adult ADHD treatment: a systematic review". Expert Review of Neurotherapeutics. 16 (2): 131–144. doi:10.1586/14737175.2016.1135735. PMID 26693882. S2CID 33004517.
Kikukawa S (May 2008). "Effectiveness of aripiprazole in treatment of adults with attention deficit disorder and restless legs syndrome". The International Journal of Neuropsychopharmacology. 11 (3): 439–440. doi:10.1017/S1461145707008310. PMID 18208634.
Brackins T, Brahm NC, Kissack JC (December 2011). "Treatments for methamphetamine abuse: a literature review for the clinician". Journal of Pharmacy Practice. 24 (6): 541–550. doi:10.1177/0897190011426557. PMID 22095579. S2CID 37335642.
Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL (June 2010). "Pharmacological approaches to methamphetamine dependence: a focused review". British Journal of Clinical Pharmacology. 69 (6): 578–592. doi:10.1111/j.1365-2125.2010.03639.x. PMC 2883750. PMID 20565449.
Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J (2008). "Pharmacotherapy of methamphetamine addiction: an update". Substance Abuse. 29 (3): 31–49. doi:10.1080/08897070802218554. PMC 2597382. PMID 19042205.

druglib.com

"Abilify (Aripiprazole) – Warnings and Precautions". DrugLib.com. 14 February 2007. Archived from the original on 4 December 2008. Retrieved 8 December 2008.
"Abilify (Aripiprazole) – Clinical Pharmacology". DrugLib.com. 14 February 2007. Archived from the original on 22 May 2008. Retrieved 8 December 2008.

drugs.com

"Aripiprazole Use During Pregnancy". Drugs.com. 22 August 2019. Archived from the original on 12 November 2020. Retrieved 7 February 2020.
"Aripiprazole (Monograph)". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 26 November 2020. Retrieved 26 February 2019.
"Aristada (aripiprazole lauroxil) FDA Approval History". Drugs.com. Archived from the original on 11 May 2018. Retrieved 11 May 2018.
"Aripiprazole (International database)". Drugs.com. 6 October 2024. Retrieved 22 October 2024.

espacenet.com

worldwide.espacenet.com

B1 EP application 0367141 B1, Oshiro Y, Sato S, Kurahashi N, "Carbostyril derivatives", published 1 October 1996, assigned to Otsuka Pharmaceutical Co., Ltd.

europa.eu

ema.europa.eu

"Abilify EPAR". European Medicines Agency. 4 June 2004. Archived from the original on 15 April 2024. Retrieved 4 July 2024.
"ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS" (PDF). European Medicines Agency. Otsuka Pharmaceutical Europe Ltd. Archived from the original (PDF) on 23 October 2013. Retrieved 22 October 2013.

ec.europa.eu

"Abilify Product information". Union Register of medicinal products. 8 June 2004. Archived from the original on 1 October 2023. Retrieved 1 October 2023.

fda.gov

"l FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada)". FDA.gov. U.S. Food and Drug Administration (FDA). 9 February 2019. Archived from the original on 2 April 2023. Retrieved 3 April 2023.
"Aripiprazole (Abilify, Abilify Maintena, Aristada): Drug Safety Communication – FDA Warns About New Impulse-control Problems". U.S. Food and Drug Administration (FDA). 3 May 2016. Archived from the original on 2 May 2019. Retrieved 4 May 2016.
"FDA approves first generic Abilify to treat mental illnesses". U.S. Food and Drug Administration (FDA). Archived from the original on 1 May 2015. Retrieved 28 April 2015.
"FDA approves pill with sensor that digitally tracks if patients have ingested their medication" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on 29 May 2019. Retrieved 29 November 2017.

accessdata.fda.gov

"Drugs@FDA: FDA-Approved Drugs". accessdata.fda.gov. Retrieved 22 October 2024.
"Patent and Exclusivity Search Results". Electronic Orange Book. U.S. Food and Drug Administration (FDA). Archived from the original on 4 May 2010. Retrieved 8 December 2008.
"Drug Approval Package: Abilify Asimtufii". accessdata.fda.gov. 16 February 2024. Archived from the original on 28 September 2024. Retrieved 27 December 2024.

fiercepharma.com

Staton T. "Pharma's Top 11 Marketing Settlements: Bristol-Myers Squibb – Abilify". FiercePharma. Archived from the original on 8 June 2017. Retrieved 4 June 2017.
Sagonowsky E (1 December 2016). "Lundbeck, Otsuka seek Abilify Maintena nod in bipolar disorder". FiercePharma. Archived from the original on 4 August 2020. Retrieved 4 June 2017.
Staton T (14 December 2016). "Bristol-Myers to pay $19.5 million in Abilify off-label marketing settlement". FiercePharma. Archived from the original on 29 October 2020. Retrieved 4 June 2017.

handle.net

hdl.handle.net

World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
De Fruyt J, Deschepper E, Audenaert K, Constant E, Floris M, Pitchot W, et al. (May 2012). "Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis". Journal of Psychopharmacology. 26 (5): 603–617. doi:10.1177/0269881111408461. hdl:2268/196468. PMID 21940761. S2CID 57249815.

harvard.edu

ui.adsabs.harvard.edu

Serezhkin VN, Savchenkov AV (2020). "Application of the Method of Molecular Voronoi–Dirichlet Polyhedra for Analysis of Noncovalent Interactions in Aripiprazole Polymorphs". Crystal Growth & Design. 20 (3): 1997–2003. Bibcode:2020CrGrD..20.1997S. doi:10.1021/acs.cgd.9b01645. S2CID 213824513.

in.gov.br

Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.

ipo.gov.uk

"Patent decision". UK Intellectual Property Office. 19 September 2006. Archived from the original on 24 November 2020. Retrieved 7 April 2015.

lundbeck.com

investor.lundbeck.com

"Press Release: Lundbeck and Otsuka Pharmaceutical sign historic agreement to deliver innovative medicines targeting psychiatric disorders worldwide (OMX:LUN)". Lundbeck. 11 November 2011. Archived from the original on 1 April 2012. Retrieved 4 June 2017.

medicines.org.uk

"Abilify Tablets, Orodispersible Tablets, Oral Solution – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Otsuka Pharmaceuticals (UK) Ltd. 20 September 2013. Archived from the original on 4 March 2016. Retrieved 22 October 2013.
"Abilify Maintena 300mg & 400mg powder and solvent for prolonged-release suspension for injection and suspension for injection in pre filled syringe – Summary of Product Characteristics (SPC)". UK Electronic Medicines Compendium. Archived from the original on 16 June 2017. Retrieved 4 June 2017.

medlineplus.gov

"Aripiprazole: MedlinePlus Drug Information". MedlinePlus. Archived from the original on 4 October 2023. Retrieved 13 October 2023.

medscape.com

reference.medscape.com

"Abilify Discmelt, Abilify Maintena (aripiprazole) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 23 October 2013. Retrieved 22 October 2013.

medscape.com

Megan Brooks (30 January 2014). "Top 100 Selling Drugs of 2013". Medscape. Archived from the original on 31 October 2015. Retrieved 15 October 2015.

nice.org.uk

"Psychosis and schizophrenia in children and young people: recognition and management". National Institute for Health and Care Excellence. UK. October 2016. Archived from the original on 22 June 2020. Retrieved 22 October 2018.
"Schizophrenia: aripiprazole prolonged-release suspension for injection | Guidance and guidelines". UK: National Institute for Health and Care Excellence. 24 July 2013. Archived from the original on 23 October 2018. Retrieved 22 October 2018.
"Bipolar disorder: assessment and management". Recommendations; Guidance and guidelines. UK: National Institute for Health and Care Excellence. 24 September 2014. Archived from the original on 6 August 2020. Retrieved 1 December 2014. 1.1 Care for adults, children, and young people across all phases of bipolar disorder
"1 Recommendations - Bipolar disorder: assessment and management - Guidance". National Institute for Health and Care Excellence. 24 September 2014. Archived from the original on 29 December 2021. Retrieved 3 April 2023.
"Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder". National Institute for Health and Care Excellence. May 2013. Archived from the original on 4 November 2022. Retrieved 3 April 2023.

nih.gov

pubmed.ncbi.nlm.nih.gov

Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, et al. (January 2014). "Aripiprazole versus other atypical antipsychotics for schizophrenia". The Cochrane Database of Systematic Reviews. 2014 (1): CD006569. doi:10.1002/14651858.CD006569.pub5. PMC 4164478. PMID 24385408.
Belgamwar RB, El-Sayeh HG (August 2011). "Aripiprazole versus placebo for schizophrenia". The Cochrane Database of Systematic Reviews (8): CD006622. doi:10.1002/14651858.CD006622.pub2. PMID 21833956.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N (11 July 2019). "Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis". The Lancet. 394 (10202): 939–951. doi:10.1016/S0140-6736(19)31135-3. PMC 6891890. PMID 31303314.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". The Lancet. 382 (9896): 951–962. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019. S2CID 32085212.
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. (February 2013). "World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects". The World Journal of Biological Psychiatry. 14 (1): 2–44. doi:10.3109/15622975.2012.739708. PMID 23216388. S2CID 28750563.
Barnes TR (May 2011). "Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology". Journal of Psychopharmacology. 25 (5): 567–620. doi:10.1177/0269881110391123. PMID 21292923. S2CID 40089561.
Brown R, Taylor MJ, Geddes J (December 2013). "Aripiprazole alone or in combination for acute mania". The Cochrane Database of Systematic Reviews. 2013 (12): CD005000. doi:10.1002/14651858.CD005000.pub2. PMC 11330668. PMID 24346956.
De Fruyt J, Deschepper E, Audenaert K, Constant E, Floris M, Pitchot W, et al. (May 2012). "Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis". Journal of Psychopharmacology. 26 (5): 603–617. doi:10.1177/0269881111408461. hdl:2268/196468. PMID 21940761. S2CID 57249815.
Gitlin M, Frye MA (May 2012). "Maintenance therapies in bipolar disorders". Bipolar Disorders. 14 (Suppl 2): 51–65. doi:10.1111/j.1399-5618.2012.00992.x. PMID 22510036. S2CID 21101054.
de Bartolomeis A, Perugi G (October 2012). "Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: from acute mania to long-term maintenance". Expert Opinion on Pharmacotherapy. 13 (14): 2027–2036. doi:10.1517/14656566.2012.719876. PMID 22946707. S2CID 39065786.
Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (March 2013). "Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes". PLOS Medicine. 10 (3): e1001403. doi:10.1371/journal.pmed.1001403. PMC 3595214. PMID 23554581.
Nelson JC, Papakostas GI (September 2009). "Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials". The American Journal of Psychiatry. 166 (9): 980–991. doi:10.1176/appi.ajp.2009.09030312. PMID 19687129.
Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S (December 2010). "Second-generation antipsychotics for major depressive disorder and dysthymia". The Cochrane Database of Systematic Reviews (12): CD008121. doi:10.1002/14651858.CD008121.pub2. PMC 11994262. PMID 21154393.
Azuma J, Hasunuma T, Kubo M, Miyatake M, Koue T, Higashi K, et al. (January 2012). "The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine". European Journal of Clinical Pharmacology. 68 (1): 29–37. doi:10.1007/s00228-011-1094-4. PMC 3249179. PMID 21739267.
Hahn M, Roll SC (December 2016). "Dosing Recommendations of Aripiprazole Depot with Strong Cytochrome P450 3A4 Inhibitors: A Relapse Risk". Drug Safety: Case Reports. 3 (1): 5. doi:10.1007/s40800-016-0027-7. PMC 5005780. PMID 27747685.
Jallaq SA, Verba M, Strawn JR, Martin LJ, DelBello MP, Ramsey LB (February 2021). "CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders". Journal of Child and Adolescent Psychopharmacology. 31 (1): 56–62. doi:10.1089/cap.2020.0058. PMC 8255312. PMID 32845723.
Hoffelt C, Gross T (January 2016). "A review of significant pharmacokinetic drug interactions with antidepressants and their management". The Mental Health Clinician. 6 (1): 35–41. doi:10.9740/mhc.2016.01.035. PMC 6009245. PMID 29955445.
Hirsch LE, Pringsheim T (June 2016). "Aripiprazole for autism spectrum disorders (ASD)". The Cochrane Database of Systematic Reviews. 2016 (6): CD009043. doi:10.1002/14651858.CD009043.pub3. PMC 7120220. PMID 27344135.
Janik P, Szejko N (2018). "Aripiprazole in treatment of Gilles de la Tourette syndrome – New therapeutic option". Neurologia I Neurochirurgia Polska. 52 (1): 84–87. doi:10.1016/j.pjnns.2017.10.015. PMID 29154107. Archived from the original on 24 December 2022. Retrieved 20 November 2021.
Müller-Vahl KR, Szejko N, Verdellen C, Roessner V, Hoekstra PJ, Hartmann A, et al. (March 2022). "European clinical guidelines for Tourette syndrome and other tic disorders: summary statement". European Child & Adolescent Psychiatry. 31 (3): 377–382. doi:10.1007/s00787-021-01832-4. PMC 8940881. PMID 34244849.
Wang S, Wei YZ, Yang JH, Zhou YM, Cheng YH, Yang C, et al. (August 2017). "The efficacy and safety of aripiprazole for tic disorders in children and adolescents: A systematic review and meta-analysis". Psychiatry Research. 254: 24–32. doi:10.1016/j.psychres.2017.04.013. PMID 28441584. S2CID 13792422.
Cox JH, Seri S, Cavanna AE (2016). "Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders". Pediatric Health, Medicine and Therapeutics. 7: 57–64. doi:10.2147/PHMT.S87121. PMC 5683285. PMID 29388585.
Zheng W, Li XB, Xiang YQ, Zhong BL, Chiu HF, Ungvari GS, et al. (January 2016). "Aripiprazole for Tourette's syndrome: a systematic review and meta-analysis". Human Psychopharmacology. 31 (1): 11–18. doi:10.1002/hup.2498. PMID 26310194. S2CID 5353158.
Yang CS, Huang H, Zhang LL, Zhu CR, Guo Q (July 2015). "Aripiprazole for the treatment of tic disorders in children: a systematic review and meta-analysis". BMC Psychiatry. 15: 179. doi:10.1186/s12888-015-0504-z. PMC 4518630. PMID 26220447.
Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J (November 2014). "Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis". BMC Psychiatry. 14 (1): 317. doi:10.1186/s12888-014-0317-5. PMC 4262998. PMID 25432131.
Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J (November 2014). "Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis". BMC Psychiatry. 14: 317. doi:10.1186/s12888-014-0317-5. PMC 4262998. PMID 25432131.
Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB (July 2007). "Practice guideline for the treatment of patients with obsessive-compulsive disorder". The American Journal of Psychiatry. 164 (7 Suppl): 5–53. PMID 17849776.
Fornaro M, Gabrielli F, Mattei C, Vinciguerra V, Fornaro P (December 2008). "Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report". Annals of General Psychiatry. 7 (1): 26. doi:10.1186/1744-859X-7-26. PMC 2621216. PMID 19105842.
Pignon B, Tezenas du Montcel C, Carton L, Pelissolo A (November 2017). "The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders". Current Psychiatry Reports. 19 (12): 103. doi:10.1007/s11920-017-0847-x. PMID 29110139. S2CID 41312623.
Grall-Bronnec M, Sauvaget A, Perrouin F, Leboucher J, Etcheverrigaray F, Challet-Bouju G, et al. (February 2016). "Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review". Journal of Clinical Psychopharmacology. 36 (1): 63–70. doi:10.1097/JCP.0000000000000444. PMC 4700874. PMID 26658263.
Moncrieff J (July 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655. S2CID 6267180.
Skov L, Johansen SS, Linnet K (January 2015). "Postmortem femoral blood reference concentrations of aripiprazole, chlorprothixene, and quetiapine". Journal of Analytical Toxicology. 39 (1): 41–44. doi:10.1093/jat/bku121. PMID 25342720.
Westerink BH, Kawahara Y, De Boer P, Geels C, De Vries JB, Wikström HV, et al. (January 2001). "Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum". European Journal of Pharmacology. 412 (2): 127–138. doi:10.1016/S0014-2999(00)00935-3. PMID 11165224.
Yanofski J (June 2010). "The dopamine dilemma: using stimulants and antipsychotics concurrently". Psychiatry. 7 (6): 18–23. PMC 2898838. PMID 20622942.
Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. (August 2003). "Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology". Neuropsychopharmacology. 28 (8): 1400–1411. doi:10.1038/sj.npp.1300203. PMID 12784105.
Mohr P, Masopust J, Kopeček M (25 January 2022). "Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?". Frontiers in Psychiatry. 12: 781946. doi:10.3389/fpsyt.2021.781946. PMC 8821167. PMID 35145438.
Keck PE, McElroy SL (April 2003). "Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic". Expert Opinion on Investigational Drugs. 12 (4): 655–662. doi:10.1517/13543784.12.4.655. PMID 12665420. S2CID 8654102.
Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. (March 2003). "H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs". Neuropsychopharmacology. 28 (3): 519–526. doi:10.1038/sj.npp.1300027. PMID 12629531.
Gaitonde SA, Avet C, de la Fuente Revenga M, Blondel-Tepaz E, Shahraki A, Pastor AM, et al. (September 2024). "Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor". Mol Psychiatry. 29 (9): 2753–2764. doi:10.1038/s41380-024-02531-7. PMC 11420065. PMID 38561467.
Starrenburg FC, Bogers JP (April 2009). "How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins". European Psychiatry. 24 (3): 164–170. doi:10.1016/j.eurpsy.2009.01.001. PMID 19285836. S2CID 42636469.
Davies MA, Sheffler DJ, Roth BL (2004). "Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology". CNS Drug Reviews. 10 (4): 317–336. doi:10.1111/j.1527-3458.2004.tb00030.x. PMC 6741761. PMID 15592581.
Pae CU, Serretti A, Patkar AA, Masand PS (2008). "Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence". CNS Drugs. 22 (5): 367–388. doi:10.2165/00023210-200822050-00002. PMID 18399707. S2CID 19757151.
Tuplin EW, Holahan MR (November 2017). "Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity". Current Neuropharmacology. 15 (8): 1192–1207. doi:10.2174/1570159X15666170413115754. PMC 5725548. PMID 28412910.
Wood M, Reavill C (June 2007). "Aripiprazole acts as a selective dopamine D2 receptor partial agonist". Expert Opinion on Investigational Drugs. 16 (6): 771–775. doi:10.1517/13543784.16.6.771. PMID 17501690. S2CID 42171115.
Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, et al. (December 2008). "Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride". Neuropsychopharmacology. 33 (13): 3111–3125. doi:10.1038/npp.2008.33. PMID 18418366.
Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, et al. (August 2002). "Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride". Neuropsychopharmacology. 27 (2): 248–259. doi:10.1016/S0893-133X(02)00304-4. PMID 12093598.
Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (April 2002). "The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor". European Journal of Pharmacology. 441 (3): 137–140. doi:10.1016/S0014-2999(02)01532-7. PMID 12063084.
Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S (September 2007). "Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study". The American Journal of Psychiatry. 164 (9): 1411–1417. doi:10.1176/appi.ajp.2007.06091479. PMID 17728427.
Mailman RB, Murthy V (May 2010). "Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?". Current Pharmaceutical Design. 16 (5): 488–501. doi:10.2174/138161210790361461. PMC 2958217. PMID 19909227.
Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. (July 2002). "Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors". The Journal of Pharmacology and Experimental Therapeutics. 302 (1): 381–389. doi:10.1124/jpet.102.033175. PMID 12065741. S2CID 12919430.
Urban JD, Vargas GA, von Zastrow M, Mailman RB (January 2007). "Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways". Neuropsychopharmacology. 32 (1): 67–77. doi:10.1038/sj.npp.1301071. PMID 16554739. S2CID 31846731.
Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, et al. (August 2002). "Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride". Neuropsychopharmacology. 27 (2): 248–259. doi:10.1016/S0893-133X(02)00304-4. PMID 12093598. S2CID 26101524.
Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, et al. (December 2008). "Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride". Neuropsychopharmacology. 33 (13): 3111–3125. doi:10.1038/npp.2008.33. PMID 18418366. S2CID 33993650.
Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. (August 2003). "Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology". Neuropsychopharmacology. 28 (8): 1400–1411. doi:10.1038/sj.npp.1300203. PMID 12784105. S2CID 22568982.
Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J (February 2006). "Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms". Biochemical Pharmacology. 71 (4): 521–529. doi:10.1016/j.bcp.2005.11.007. PMID 16336943.
Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, et al. (June 1999). "Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes". Neuropsychopharmacology. 20 (6): 612–627. doi:10.1016/S0893-133X(98)00099-2. PMID 10327430.
Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, Di Pace C, et al. (2014). "Clinical pharmacology of atypical antipsychotics: an update". EXCLI Journal. 13: 1163–1191. PMC 4464358. PMID 26417330.
Kessler RM (September 2007). "Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?". The American Journal of Psychiatry. 164 (9): 1310–1312. doi:10.1176/appi.ajp.2007.07071043. PMID 17728411. S2CID 1891586.
Jørgensen A, Overø KF (1980). "Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels". Acta Psychiatrica Scandinavica. Supplementum. 279: 41–54. doi:10.1111/j.1600-0447.1980.tb07082.x. PMID 6931472.
Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR (May 1984). "Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches". The Journal of Clinical Psychiatry. 45 (5 Pt 2): 50–9. PMID 6143748.
Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA (April 1979). "Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man". British Journal of Clinical Pharmacology. 7 (4): 325–31. doi:10.1111/j.1365-2125.1979.tb00941.x. PMC 1429660. PMID 444352.
Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Verbruggen FJ, van Nueten JM, et al. (November 1970). "The pharmacology of fluspirilene (R 6218), a potent, long-acting and injectable neuroleptic drug". Arzneimittel-Forschung. 20 (11): 1689–98. PMID 4992598.
Beresford R, Ward A (January 1987). "Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis". Drugs. 33 (1): 31–49. doi:10.2165/00003495-198733010-00002. PMID 3545764.
Reyntigens AJ, Heykants JJ, Woestenborghs RJ, Gelders YG, Aerts TJ (1982). "Pharmacokinetics of haloperidol decanoate. A 2-year follow-up". International Pharmacopsychiatry. 17 (4): 238–46. doi:10.1159/000468580. PMID 7185768.
Warren LR, McGowan E, Renton M, Morrison CA, Funnell NP (October 2021). "Direct evidence for distinct colour origins in ROY polymorphs". Chemical Science. 12 (38): 12711–12718. doi:10.1039/d1sc04051k. PMC 8494124. PMID 34703557.
Grady MA, Gasperoni TL, Kirkpatrick P (June 2003). "Aripiprazole". Nature Reviews. Drug Discovery. 2 (6): 427–428. doi:10.1038/nrd1114. PMID 12790153.
de Bartolomeis A, Tomasetti C, Iasevoli F (September 2015). "Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism". CNS Drugs. 29 (9): 773–799. doi:10.1007/s40263-015-0278-3. PMC 4602118. PMID 26346901.
Kikuchi T, Maeda K, Suzuki M, Hirose T, Futamura T, McQuade RD (June 2021). "Discovery research and development history of the dopamine D₂ receptor partial agonists, aripiprazole and brexpiprazole". Neuropsychopharmacology Reports. 41 (2): 134–143. doi:10.1002/npr2.12180. PMC 8340839. PMID 33960741.
Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, et al. (July 1995). "7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity". The Journal of Pharmacology and Experimental Therapeutics. 274 (1): 329–336. doi:10.1016/S0022-3565(25)10600-9. PMID 7616416.
Citrome L (2015). "Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil". Expert Review of Clinical Pharmacology. 9 (2): 169–186. doi:10.1586/17512433.2016.1121809. PMID 26573020. S2CID 207208248.
Casey AB, Canal CE (June 2017). "Classics in Chemical Neuroscience: Aripiprazole". ACS Chemical Neuroscience. 8 (6): 1135–1146. doi:10.1021/acschemneuro.7b00087. PMC 5495458. PMID 28368577.
De Crescenzo F, Cortese S, Adamo N, Janiri L (February 2017). "Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review". Evidence-Based Mental Health. 20 (1): 4–11. doi:10.1136/eb-2016-102415. PMC 10699262. PMID 27993933. S2CID 24904076.
Ghanizadeh A (October 2013). "Systematic review of clinical trials of aripiprazole for treating attention deficit hyperactivity disorder". Neurosciences. 18 (4): 323–329. PMID 24141455.
Buoli M, Serati M, Cahn W (2016). "Alternative pharmacological strategies for adult ADHD treatment: a systematic review". Expert Review of Neurotherapeutics. 16 (2): 131–144. doi:10.1586/14737175.2016.1135735. PMID 26693882. S2CID 33004517.
Kikukawa S (May 2008). "Effectiveness of aripiprazole in treatment of adults with attention deficit disorder and restless legs syndrome". The International Journal of Neuropsychopharmacology. 11 (3): 439–440. doi:10.1017/S1461145707008310. PMID 18208634.
Brackins T, Brahm NC, Kissack JC (December 2011). "Treatments for methamphetamine abuse: a literature review for the clinician". Journal of Pharmacy Practice. 24 (6): 541–550. doi:10.1177/0897190011426557. PMID 22095579. S2CID 37335642.
Brunetti M, Di Tizio L, Dezi S, Pozzi G, Grandinetti P, Martinotti G (October 2012). "Aripiprazole, alcohol and substance abuse: a review". European Review for Medical and Pharmacological Sciences. 16 (10): 1346–1354. PMID 23104650.
Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL (June 2010). "Pharmacological approaches to methamphetamine dependence: a focused review". British Journal of Clinical Pharmacology. 69 (6): 578–592. doi:10.1111/j.1365-2125.2010.03639.x. PMC 2883750. PMID 20565449.
Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J (2008). "Pharmacotherapy of methamphetamine addiction: an update". Substance Abuse. 29 (3): 31–49. doi:10.1080/08897070802218554. PMC 2597382. PMID 19042205.

ncbi.nlm.nih.gov

Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, et al. (January 2014). "Aripiprazole versus other atypical antipsychotics for schizophrenia". The Cochrane Database of Systematic Reviews. 2014 (1): CD006569. doi:10.1002/14651858.CD006569.pub5. PMC 4164478. PMID 24385408.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N (11 July 2019). "Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis". The Lancet. 394 (10202): 939–951. doi:10.1016/S0140-6736(19)31135-3. PMC 6891890. PMID 31303314.
Brown R, Taylor MJ, Geddes J (December 2013). "Aripiprazole alone or in combination for acute mania". The Cochrane Database of Systematic Reviews. 2013 (12): CD005000. doi:10.1002/14651858.CD005000.pub2. PMC 11330668. PMID 24346956.
Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (March 2013). "Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes". PLOS Medicine. 10 (3): e1001403. doi:10.1371/journal.pmed.1001403. PMC 3595214. PMID 23554581.
Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S (December 2010). "Second-generation antipsychotics for major depressive disorder and dysthymia". The Cochrane Database of Systematic Reviews (12): CD008121. doi:10.1002/14651858.CD008121.pub2. PMC 11994262. PMID 21154393.
Azuma J, Hasunuma T, Kubo M, Miyatake M, Koue T, Higashi K, et al. (January 2012). "The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine". European Journal of Clinical Pharmacology. 68 (1): 29–37. doi:10.1007/s00228-011-1094-4. PMC 3249179. PMID 21739267.
Hahn M, Roll SC (December 2016). "Dosing Recommendations of Aripiprazole Depot with Strong Cytochrome P450 3A4 Inhibitors: A Relapse Risk". Drug Safety: Case Reports. 3 (1): 5. doi:10.1007/s40800-016-0027-7. PMC 5005780. PMID 27747685.
Jallaq SA, Verba M, Strawn JR, Martin LJ, DelBello MP, Ramsey LB (February 2021). "CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders". Journal of Child and Adolescent Psychopharmacology. 31 (1): 56–62. doi:10.1089/cap.2020.0058. PMC 8255312. PMID 32845723.
Hoffelt C, Gross T (January 2016). "A review of significant pharmacokinetic drug interactions with antidepressants and their management". The Mental Health Clinician. 6 (1): 35–41. doi:10.9740/mhc.2016.01.035. PMC 6009245. PMID 29955445.
Hirsch LE, Pringsheim T (June 2016). "Aripiprazole for autism spectrum disorders (ASD)". The Cochrane Database of Systematic Reviews. 2016 (6): CD009043. doi:10.1002/14651858.CD009043.pub3. PMC 7120220. PMID 27344135.
Müller-Vahl KR, Szejko N, Verdellen C, Roessner V, Hoekstra PJ, Hartmann A, et al. (March 2022). "European clinical guidelines for Tourette syndrome and other tic disorders: summary statement". European Child & Adolescent Psychiatry. 31 (3): 377–382. doi:10.1007/s00787-021-01832-4. PMC 8940881. PMID 34244849.
Cox JH, Seri S, Cavanna AE (2016). "Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders". Pediatric Health, Medicine and Therapeutics. 7: 57–64. doi:10.2147/PHMT.S87121. PMC 5683285. PMID 29388585.
Yang CS, Huang H, Zhang LL, Zhu CR, Guo Q (July 2015). "Aripiprazole for the treatment of tic disorders in children: a systematic review and meta-analysis". BMC Psychiatry. 15: 179. doi:10.1186/s12888-015-0504-z. PMC 4518630. PMID 26220447.
Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J (November 2014). "Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis". BMC Psychiatry. 14 (1): 317. doi:10.1186/s12888-014-0317-5. PMC 4262998. PMID 25432131.
Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J (November 2014). "Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis". BMC Psychiatry. 14: 317. doi:10.1186/s12888-014-0317-5. PMC 4262998. PMID 25432131.
Fornaro M, Gabrielli F, Mattei C, Vinciguerra V, Fornaro P (December 2008). "Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report". Annals of General Psychiatry. 7 (1): 26. doi:10.1186/1744-859X-7-26. PMC 2621216. PMID 19105842.
Grall-Bronnec M, Sauvaget A, Perrouin F, Leboucher J, Etcheverrigaray F, Challet-Bouju G, et al. (February 2016). "Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review". Journal of Clinical Psychopharmacology. 36 (1): 63–70. doi:10.1097/JCP.0000000000000444. PMC 4700874. PMID 26658263.
Yanofski J (June 2010). "The dopamine dilemma: using stimulants and antipsychotics concurrently". Psychiatry. 7 (6): 18–23. PMC 2898838. PMID 20622942.
Mohr P, Masopust J, Kopeček M (25 January 2022). "Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?". Frontiers in Psychiatry. 12: 781946. doi:10.3389/fpsyt.2021.781946. PMC 8821167. PMID 35145438.
Gaitonde SA, Avet C, de la Fuente Revenga M, Blondel-Tepaz E, Shahraki A, Pastor AM, et al. (September 2024). "Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor". Mol Psychiatry. 29 (9): 2753–2764. doi:10.1038/s41380-024-02531-7. PMC 11420065. PMID 38561467.
Davies MA, Sheffler DJ, Roth BL (2004). "Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology". CNS Drug Reviews. 10 (4): 317–336. doi:10.1111/j.1527-3458.2004.tb00030.x. PMC 6741761. PMID 15592581.
Tuplin EW, Holahan MR (November 2017). "Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity". Current Neuropharmacology. 15 (8): 1192–1207. doi:10.2174/1570159X15666170413115754. PMC 5725548. PMID 28412910.
Mailman RB, Murthy V (May 2010). "Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?". Current Pharmaceutical Design. 16 (5): 488–501. doi:10.2174/138161210790361461. PMC 2958217. PMID 19909227.
Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, Di Pace C, et al. (2014). "Clinical pharmacology of atypical antipsychotics: an update". EXCLI Journal. 13: 1163–1191. PMC 4464358. PMID 26417330.
Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA (April 1979). "Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man". British Journal of Clinical Pharmacology. 7 (4): 325–31. doi:10.1111/j.1365-2125.1979.tb00941.x. PMC 1429660. PMID 444352.
Warren LR, McGowan E, Renton M, Morrison CA, Funnell NP (October 2021). "Direct evidence for distinct colour origins in ROY polymorphs". Chemical Science. 12 (38): 12711–12718. doi:10.1039/d1sc04051k. PMC 8494124. PMID 34703557.
de Bartolomeis A, Tomasetti C, Iasevoli F (September 2015). "Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism". CNS Drugs. 29 (9): 773–799. doi:10.1007/s40263-015-0278-3. PMC 4602118. PMID 26346901.
Kikuchi T, Maeda K, Suzuki M, Hirose T, Futamura T, McQuade RD (June 2021). "Discovery research and development history of the dopamine D₂ receptor partial agonists, aripiprazole and brexpiprazole". Neuropsychopharmacology Reports. 41 (2): 134–143. doi:10.1002/npr2.12180. PMC 8340839. PMID 33960741.
Casey AB, Canal CE (June 2017). "Classics in Chemical Neuroscience: Aripiprazole". ACS Chemical Neuroscience. 8 (6): 1135–1146. doi:10.1021/acschemneuro.7b00087. PMC 5495458. PMID 28368577.
De Crescenzo F, Cortese S, Adamo N, Janiri L (February 2017). "Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review". Evidence-Based Mental Health. 20 (1): 4–11. doi:10.1136/eb-2016-102415. PMC 10699262. PMID 27993933. S2CID 24904076.
Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL (June 2010). "Pharmacological approaches to methamphetamine dependence: a focused review". British Journal of Clinical Pharmacology. 69 (6): 578–592. doi:10.1111/j.1365-2125.2010.03639.x. PMC 2883750. PMID 20565449.
Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J (2008). "Pharmacotherapy of methamphetamine addiction: an update". Substance Abuse. 29 (3): 31–49. doi:10.1080/08897070802218554. PMC 2597382. PMID 19042205.

dailymed.nlm.nih.gov

"Abilify- aripiprazole tablet Abilify- aripiprazole solution Abilify- aripiprazole tablet, orally disintegrating Abilify- aripiprazole injection, solution". DailyMed. Archived from the original on 3 December 2020. Retrieved 20 October 2020.
"Abilify Asimtufii- aripiprazole injection, suspension, extended release". DailyMed. 30 January 2024. Retrieved 27 December 2024.
"Abilify Maintena- aripiprazole kit". DailyMed. 30 January 2025. Retrieved 16 February 2025.
"Abilify Mycite- aripiprazole tablet with sensor". DailyMed. 31 January 2025. Retrieved 16 February 2025.

nytimes.com

Belluck P (13 November 2017). "First Digital Pill Approved to Worries About Biomedical 'Big Brother'". The New York Times. ISSN 0362-4331. Archived from the original on 28 November 2017. Retrieved 29 November 2017.

otsuka.co.jp

"Otsuka's Antipsychotic Abilify Is Approved in Japan, January 23, 2006｜News Releases". Otsuka Pharmaceutical Co., Ltd. Archived from the original on 4 July 2024. Retrieved 6 October 2022.

pharmaceutical-technology.com

"Otsuka and Lundbeck's schizophrenia treatment gains EC approval". Pharmaceutical Technology. 28 March 2024. Archived from the original on 4 July 2024. Retrieved 16 April 2024.

pharmacytimes.com

"FDA Approves Aripiprazole as First Once-Every-2-Months Long-Acting Injectable for Schizophrenia, Bipolar I Disorder". Pharmacy Times. 28 April 2023. Archived from the original on 30 May 2024. Retrieved 16 April 2024.

pmlive.com

"BMS cuts salesforce on revised Abilify deal". PM Live. 7 November 2012. Archived from the original on 26 September 2020. Retrieved 4 June 2017.

psa.org.au

"Australian Medicines Handbook 2013 [Internet]". Archived from the original on 25 September 2013. Retrieved 20 September 2013.

rcpsych.ac.uk

"The risks and benefits of high dose antipsychotic medication" (PDF). Royal College of Psychiatrists. 10 November 2014. Archived (PDF) from the original on 4 July 2024. Retrieved 16 April 2024.

reuters.com

Keating G (23 November 2009). "FDA OKs Abilify for child autism irritability". Reuters. Archived from the original on 25 January 2010. Retrieved 22 September 2010.

semanticscholar.org

api.semanticscholar.org

Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". The Lancet. 382 (9896): 951–962. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019. S2CID 32085212.
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. (February 2013). "World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects". The World Journal of Biological Psychiatry. 14 (1): 2–44. doi:10.3109/15622975.2012.739708. PMID 23216388. S2CID 28750563.
Barnes TR (May 2011). "Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology". Journal of Psychopharmacology. 25 (5): 567–620. doi:10.1177/0269881110391123. PMID 21292923. S2CID 40089561.
De Fruyt J, Deschepper E, Audenaert K, Constant E, Floris M, Pitchot W, et al. (May 2012). "Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis". Journal of Psychopharmacology. 26 (5): 603–617. doi:10.1177/0269881111408461. hdl:2268/196468. PMID 21940761. S2CID 57249815.
Gitlin M, Frye MA (May 2012). "Maintenance therapies in bipolar disorders". Bipolar Disorders. 14 (Suppl 2): 51–65. doi:10.1111/j.1399-5618.2012.00992.x. PMID 22510036. S2CID 21101054.
de Bartolomeis A, Perugi G (October 2012). "Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: from acute mania to long-term maintenance". Expert Opinion on Pharmacotherapy. 13 (14): 2027–2036. doi:10.1517/14656566.2012.719876. PMID 22946707. S2CID 39065786.
Wang S, Wei YZ, Yang JH, Zhou YM, Cheng YH, Yang C, et al. (August 2017). "The efficacy and safety of aripiprazole for tic disorders in children and adolescents: A systematic review and meta-analysis". Psychiatry Research. 254: 24–32. doi:10.1016/j.psychres.2017.04.013. PMID 28441584. S2CID 13792422.
Zheng W, Li XB, Xiang YQ, Zhong BL, Chiu HF, Ungvari GS, et al. (January 2016). "Aripiprazole for Tourette's syndrome: a systematic review and meta-analysis". Human Psychopharmacology. 31 (1): 11–18. doi:10.1002/hup.2498. PMID 26310194. S2CID 5353158.
Pignon B, Tezenas du Montcel C, Carton L, Pelissolo A (November 2017). "The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders". Current Psychiatry Reports. 19 (12): 103. doi:10.1007/s11920-017-0847-x. PMID 29110139. S2CID 41312623.
Moncrieff J (July 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655. S2CID 6267180.
Keck PE, McElroy SL (April 2003). "Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic". Expert Opinion on Investigational Drugs. 12 (4): 655–662. doi:10.1517/13543784.12.4.655. PMID 12665420. S2CID 8654102.
Starrenburg FC, Bogers JP (April 2009). "How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins". European Psychiatry. 24 (3): 164–170. doi:10.1016/j.eurpsy.2009.01.001. PMID 19285836. S2CID 42636469.
Pae CU, Serretti A, Patkar AA, Masand PS (2008). "Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence". CNS Drugs. 22 (5): 367–388. doi:10.2165/00023210-200822050-00002. PMID 18399707. S2CID 19757151.
Wood M, Reavill C (June 2007). "Aripiprazole acts as a selective dopamine D2 receptor partial agonist". Expert Opinion on Investigational Drugs. 16 (6): 771–775. doi:10.1517/13543784.16.6.771. PMID 17501690. S2CID 42171115.
Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. (July 2002). "Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors". The Journal of Pharmacology and Experimental Therapeutics. 302 (1): 381–389. doi:10.1124/jpet.102.033175. PMID 12065741. S2CID 12919430.
Urban JD, Vargas GA, von Zastrow M, Mailman RB (January 2007). "Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways". Neuropsychopharmacology. 32 (1): 67–77. doi:10.1038/sj.npp.1301071. PMID 16554739. S2CID 31846731.
Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, et al. (August 2002). "Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride". Neuropsychopharmacology. 27 (2): 248–259. doi:10.1016/S0893-133X(02)00304-4. PMID 12093598. S2CID 26101524.
Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, et al. (December 2008). "Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride". Neuropsychopharmacology. 33 (13): 3111–3125. doi:10.1038/npp.2008.33. PMID 18418366. S2CID 33993650.
Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. (August 2003). "Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology". Neuropsychopharmacology. 28 (8): 1400–1411. doi:10.1038/sj.npp.1300203. PMID 12784105. S2CID 22568982.
Kessler RM (September 2007). "Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?". The American Journal of Psychiatry. 164 (9): 1310–1312. doi:10.1176/appi.ajp.2007.07071043. PMID 17728411. S2CID 1891586.
Serezhkin VN, Savchenkov AV (2020). "Application of the Method of Molecular Voronoi–Dirichlet Polyhedra for Analysis of Noncovalent Interactions in Aripiprazole Polymorphs". Crystal Growth & Design. 20 (3): 1997–2003. Bibcode:2020CrGrD..20.1997S. doi:10.1021/acs.cgd.9b01645. S2CID 213824513.
Citrome L (2015). "Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil". Expert Review of Clinical Pharmacology. 9 (2): 169–186. doi:10.1586/17512433.2016.1121809. PMID 26573020. S2CID 207208248.
De Crescenzo F, Cortese S, Adamo N, Janiri L (February 2017). "Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review". Evidence-Based Mental Health. 20 (1): 4–11. doi:10.1136/eb-2016-102415. PMC 10699262. PMID 27993933. S2CID 24904076.
Buoli M, Serati M, Cahn W (2016). "Alternative pharmacological strategies for adult ADHD treatment: a systematic review". Expert Review of Neurotherapeutics. 16 (2): 131–144. doi:10.1586/14737175.2016.1135735. PMID 26693882. S2CID 33004517.
Brackins T, Brahm NC, Kissack JC (December 2011). "Treatments for methamphetamine abuse: a literature review for the clinician". Journal of Pharmacy Practice. 24 (6): 541–550. doi:10.1177/0897190011426557. PMID 22095579. S2CID 37335642.

springer.com

adisinsight.springer.com

"Aripiprazole". adisInsight. springer.com. Springer. Archived from the original on 2 October 2017. Retrieved 21 September 2021.

tevapharm.com

"Latest News | Teva Pharmaceuticals". www.tevapharm.com. 20 May 2023. Archived from the original on 24 December 2022. Retrieved 24 December 2022.

tga.gov.au

https://www.tga.gov.au/resources/prescription-medicines-registrations/aripena-sun-pharma-anz-pty-ltd
"Prescribing medicines in pregnancy database". Australian Government. 3 March 2014. Archived from the original on 8 April 2014. Retrieved 22 April 2014.

ebs.tga.gov.au

"Product Information for Abilify Aripiprazole Tablets & Orally Disintegrating Tablets". TGA eBusiness Services. Bristol-Myers Squibb Australia Pty Ltd. 1 November 2012. Archived from the original on 10 November 2017. Retrieved 22 October 2013.

thedailybeast.com

Michaelson J (9 November 2014). "Mother's Little Anti-Psychotic Is Worth $6.9 Billion A Year". The Daily Beast. Archived from the original on 18 March 2017. Retrieved 10 November 2014.

thelegalintelligencer.com

Mitchell M (8 December 2016). "Bristol-Myers Squibb Agrees to $19.5M Settlement Over Abilify Marketing". The Legal Intelligencer. Archived from the original on 27 August 2021. Retrieved 4 June 2017.

thepharmaletter.com

"B-MS reveals Ph III aripiprazole data – Pharmaceutical industry news". The Pharma Letter. 17 May 2000. Archived from the original on 27 January 2019. Retrieved 4 June 2017.

unc.edu

pdsp.unc.edu

Roth BL, Driscol J. "PDSP K_i Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Archived from the original on 27 August 2021. Retrieved 14 August 2017.

viamedica.pl

journals.viamedica.pl

Janik P, Szejko N (2018). "Aripiprazole in treatment of Gilles de la Tourette syndrome – New therapeutic option". Neurologia I Neurochirurgia Polska. 52 (1): 84–87. doi:10.1016/j.pjnns.2017.10.015. PMID 29154107. Archived from the original on 24 December 2022. Retrieved 20 November 2021.

web.archive.org

"Aripiprazole Use During Pregnancy". Drugs.com. 22 August 2019. Archived from the original on 12 November 2020. Retrieved 7 February 2020.
Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
"Abilify- aripiprazole tablet Abilify- aripiprazole solution Abilify- aripiprazole tablet, orally disintegrating Abilify- aripiprazole injection, solution". DailyMed. Archived from the original on 3 December 2020. Retrieved 20 October 2020.
"Abilify EPAR". European Medicines Agency. 4 June 2004. Archived from the original on 15 April 2024. Retrieved 4 July 2024.
"Abilify Tablets, Orodispersible Tablets, Oral Solution – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Otsuka Pharmaceuticals (UK) Ltd. 20 September 2013. Archived from the original on 4 March 2016. Retrieved 22 October 2013.
"ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS" (PDF). European Medicines Agency. Otsuka Pharmaceutical Europe Ltd. Archived from the original (PDF) on 23 October 2013. Retrieved 22 October 2013.
"Aripiprazole (Monograph)". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 26 November 2020. Retrieved 26 February 2019.
"Prescribing medicines in pregnancy database". Australian Government. 3 March 2014. Archived from the original on 8 April 2014. Retrieved 22 April 2014.
"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Psychosis and schizophrenia in children and young people: recognition and management". National Institute for Health and Care Excellence. UK. October 2016. Archived from the original on 22 June 2020. Retrieved 22 October 2018.
"Schizophrenia: aripiprazole prolonged-release suspension for injection | Guidance and guidelines". UK: National Institute for Health and Care Excellence. 24 July 2013. Archived from the original on 23 October 2018. Retrieved 22 October 2018.
"Bipolar disorder: assessment and management". Recommendations; Guidance and guidelines. UK: National Institute for Health and Care Excellence. 24 September 2014. Archived from the original on 6 August 2020. Retrieved 1 December 2014. 1.1 Care for adults, children, and young people across all phases of bipolar disorder
"1 Recommendations - Bipolar disorder: assessment and management - Guidance". National Institute for Health and Care Excellence. 24 September 2014. Archived from the original on 29 December 2021. Retrieved 3 April 2023.
"Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder". National Institute for Health and Care Excellence. May 2013. Archived from the original on 4 November 2022. Retrieved 3 April 2023.
"The risks and benefits of high dose antipsychotic medication" (PDF). Royal College of Psychiatrists. 10 November 2014. Archived (PDF) from the original on 4 July 2024. Retrieved 16 April 2024.
"Product Information for Abilify Aripiprazole Tablets & Orally Disintegrating Tablets". TGA eBusiness Services. Bristol-Myers Squibb Australia Pty Ltd. 1 November 2012. Archived from the original on 10 November 2017. Retrieved 22 October 2013.
"Aripiprazole". adisInsight. springer.com. Springer. Archived from the original on 2 October 2017. Retrieved 21 September 2021.
Janik P, Szejko N (2018). "Aripiprazole in treatment of Gilles de la Tourette syndrome – New therapeutic option". Neurologia I Neurochirurgia Polska. 52 (1): 84–87. doi:10.1016/j.pjnns.2017.10.015. PMID 29154107. Archived from the original on 24 December 2022. Retrieved 20 November 2021.
"l FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada)". FDA.gov. U.S. Food and Drug Administration (FDA). 9 February 2019. Archived from the original on 2 April 2023. Retrieved 3 April 2023.
"Aripiprazole: MedlinePlus Drug Information". MedlinePlus. Archived from the original on 4 October 2023. Retrieved 13 October 2023.
"Abilify Discmelt, Abilify Maintena (aripiprazole) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 23 October 2013. Retrieved 22 October 2013.
"Aripiprazole (Abilify, Abilify Maintena, Aristada): Drug Safety Communication – FDA Warns About New Impulse-control Problems". U.S. Food and Drug Administration (FDA). 3 May 2016. Archived from the original on 2 May 2019. Retrieved 4 May 2016.
Haddad P, Haddad PM, Dursun S, Deakin B (2004). Adverse Syndromes and Psychiatric Drugs: A Clinical Guide. OUP Oxford. pp. 207–216. ISBN 978-0-19-852748-0. Archived from the original on 10 January 2023. Retrieved 19 September 2020.
Sacchetti E, Vita A, Siracusano A, Fleischhacker W (2013). Adherence to Antipsychotics in Schizophrenia. Springer Science & Business Media. p. 85. ISBN 9788847026797. Archived from the original on 10 January 2023. Retrieved 19 September 2020.
"Abilify (Aripiprazole) – Warnings and Precautions". DrugLib.com. 14 February 2007. Archived from the original on 4 December 2008. Retrieved 8 December 2008.
Roth BL, Driscol J. "PDSP K_i Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Archived from the original on 27 August 2021. Retrieved 14 August 2017.
"Abilify (Aripiprazole) – Clinical Pharmacology". DrugLib.com. 14 February 2007. Archived from the original on 22 May 2008. Retrieved 8 December 2008.
Behere PB, Das A, Behere AP (2018). Clinical Psychopharmacology: An Update. Springer. p. 66. ISBN 9789811320927. Archived from the original on 4 July 2024. Retrieved 19 September 2020.
"Otsuka's Antipsychotic Abilify Is Approved in Japan, January 23, 2006｜News Releases". Otsuka Pharmaceutical Co., Ltd. Archived from the original on 4 July 2024. Retrieved 6 October 2022.
"B-MS reveals Ph III aripiprazole data – Pharmaceutical industry news". The Pharma Letter. 17 May 2000. Archived from the original on 27 January 2019. Retrieved 4 June 2017.
"Abilify Product information". Union Register of medicinal products. 8 June 2004. Archived from the original on 1 October 2023. Retrieved 1 October 2023.
Hitti M (20 November 2007). "FDA OKs Abilify for Depression". WebMD. Archived from the original on 5 December 2008. Retrieved 8 December 2008.
Keating G (23 November 2009). "FDA OKs Abilify for child autism irritability". Reuters. Archived from the original on 25 January 2010. Retrieved 22 September 2010.
"Patent and Exclusivity Search Results". Electronic Orange Book. U.S. Food and Drug Administration (FDA). Archived from the original on 4 May 2010. Retrieved 8 December 2008.
Mitchell M (8 December 2016). "Bristol-Myers Squibb Agrees to $19.5M Settlement Over Abilify Marketing". The Legal Intelligencer. Archived from the original on 27 August 2021. Retrieved 4 June 2017.
Staton T. "Pharma's Top 11 Marketing Settlements: Bristol-Myers Squibb – Abilify". FiercePharma. Archived from the original on 8 June 2017. Retrieved 4 June 2017.
"Press Release: Lundbeck and Otsuka Pharmaceutical sign historic agreement to deliver innovative medicines targeting psychiatric disorders worldwide (OMX:LUN)". Lundbeck. 11 November 2011. Archived from the original on 1 April 2012. Retrieved 4 June 2017.
Megan Brooks (30 January 2014). "Top 100 Selling Drugs of 2013". Medscape. Archived from the original on 31 October 2015. Retrieved 15 October 2015.
"BMS cuts salesforce on revised Abilify deal". PM Live. 7 November 2012. Archived from the original on 26 September 2020. Retrieved 4 June 2017.
Sagonowsky E (1 December 2016). "Lundbeck, Otsuka seek Abilify Maintena nod in bipolar disorder". FiercePharma. Archived from the original on 4 August 2020. Retrieved 4 June 2017.
"Abilify Maintena 300mg & 400mg powder and solvent for prolonged-release suspension for injection and suspension for injection in pre filled syringe – Summary of Product Characteristics (SPC)". UK Electronic Medicines Compendium. Archived from the original on 16 June 2017. Retrieved 4 June 2017.
"Barr Confirms Filing an Application with a Paragraph IV Certification for Abilify Tablets" (Press release). Barr Pharmaceuticals, Inc. 20 March 2007. Archived from the original on 16 September 2018. Retrieved 23 December 2008.
Decker S, Randall T (15 November 2010). "Bristol-Myers Partner Otsuka Wins Abilify Ruling – Bloomberg Business". Bloomberg L.P. Archived from the original on 22 July 2016. Retrieved 13 May 2015.
"Patent decision". UK Intellectual Property Office. 19 September 2006. Archived from the original on 24 November 2020. Retrieved 7 April 2015.
Michaelson J (9 November 2014). "Mother's Little Anti-Psychotic Is Worth $6.9 Billion A Year". The Daily Beast. Archived from the original on 18 March 2017. Retrieved 10 November 2014.
"FDA approves first generic Abilify to treat mental illnesses". U.S. Food and Drug Administration (FDA). Archived from the original on 1 May 2015. Retrieved 28 April 2015.
"Latest News | Teva Pharmaceuticals". www.tevapharm.com. 20 May 2023. Archived from the original on 24 December 2022. Retrieved 24 December 2022.
"Aristada (aripiprazole lauroxil) FDA Approval History". Drugs.com. Archived from the original on 11 May 2018. Retrieved 11 May 2018.
Staton T (14 December 2016). "Bristol-Myers to pay $19.5 million in Abilify off-label marketing settlement". FiercePharma. Archived from the original on 29 October 2020. Retrieved 4 June 2017.
"FDA approves pill with sensor that digitally tracks if patients have ingested their medication" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on 29 May 2019. Retrieved 29 November 2017.
Belluck P (13 November 2017). "First Digital Pill Approved to Worries About Biomedical 'Big Brother'". The New York Times. ISSN 0362-4331. Archived from the original on 28 November 2017. Retrieved 29 November 2017.
"Drug Approval Package: Abilify Asimtufii". accessdata.fda.gov. 16 February 2024. Archived from the original on 28 September 2024. Retrieved 27 December 2024.
"FDA Approves Aripiprazole as First Once-Every-2-Months Long-Acting Injectable for Schizophrenia, Bipolar I Disorder". Pharmacy Times. 28 April 2023. Archived from the original on 30 May 2024. Retrieved 16 April 2024.
"Otsuka and Lundbeck's schizophrenia treatment gains EC approval". Pharmaceutical Technology. 28 March 2024. Archived from the original on 4 July 2024. Retrieved 16 April 2024.
"Australian Medicines Handbook 2013 [Internet]". Archived from the original on 25 September 2013. Retrieved 20 September 2013.

webmd.com

Hitti M (20 November 2007). "FDA OKs Abilify for Depression". WebMD. Archived from the original on 5 December 2008. Retrieved 8 December 2008.

worldcat.org

search.worldcat.org

Belluck P (13 November 2017). "First Digital Pill Approved to Worries About Biomedical 'Big Brother'". The New York Times. ISSN 0362-4331. Archived from the original on 28 November 2017. Retrieved 29 November 2017.